Today: 23 January 2026
Subscribe
Browse Category

Pharmaceuticals News 22 December 2025 - 23 December 2025

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates. Below is a comprehensive roundup…
23 December 2025
····
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck & Co., Inc. (NYSE: MRK) is closing in on year-end with a rare mix of policy-driven headlines, regulatory acceleration, and pipeline catalysts that are shaping investor expectations for 2026 and beyond. From a White House-backed drug-pricing framework that offers tariff relief to drugmakers, to the FDA’s fast-track voucher program attaching itself to two Merck assets with blockbuster potential, MRK…
23 December 2025
····
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

December 23, 2025 — Novo Nordisk A/S (NYSE: NVO) is back in the spotlight after U.S. regulators approved a pill version of Wegovy, a milestone that could reshape the fast-growing obesity drug market—and potentially reset the narrative around a stock that’s had a bruising 2025. In U.S. trading on Dec. 23, Novo Nordisk shares traded around $52, up roughly 9%…
23 December 2025
···
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. (NYSE: PFE) stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow…
23 December 2025
····
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk A/S (NYSE: NVO) is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and…
23 December 2025
····
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb Company (NYSE: BMY) ended Monday’s regular session on a modestly stronger note, then held near flat in after-hours trading as investors continued to weigh a fast-evolving U.S. drug-pricing landscape, BMS’s Eliquis-focused policy commitments, and a fresh dividend hike headed into 2026. Below is what’s moving BMY after the bell on December 22, 2025, and the key items investors…
23 December 2025
····
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Dec. 22, 2025 — After the closing bell, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is finishing the day in the spotlight for a reason that has nothing to do with a clinical readout—at least not directly. Monday marked the company’s first trading day as a Nasdaq-100 constituent, a mechanical event that can reshape near-term flows even when the underlying business story…
23 December 2025
····
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” (oral semaglutide 25 mg) for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk For Novo Nordisk, the milestone is more than a product expansion. It’s…
23 December 2025
·
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly and Company (NYSE: LLY) ended Monday’s regular session higher — then slipped after the closing bell as investors digested a major late-day headline from its biggest obesity rival, Novo Nordisk. LLY closed at $1,076.48 (+0.47%) at 4:00 p.m. ET on Monday, Dec. 22, 2025, then traded down about 1% in after-hours action, around $1,065.50 as of 6:18 p.m.…
23 December 2025
···
AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Inc. (NYSE: ABBV) is trading near recent highs on Monday, December 22, 2025, as investors weigh a powerful mix of policy risk, shareholder returns, and pipeline momentum heading into 2026. The big near-term variable isn’t a clinical readout—it’s Washington. After the White House unveiled sweeping “most-favored-nation” (MFN) drug-pricing agreements with nine large manufacturers on December 19, AbbVie remains one…
22 December 2025
····
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Inc. (NASDAQ: AMGN) is back in the spotlight on Monday, December 22, 2025, as investors weigh a wave of White House drug‑pricing agreements, a fast‑moving “most‑favored‑nation” (MFN) pricing push, and what it could all mean for Amgen’s earnings power in 2026. The stock traded higher in Monday’s session, with market data showing shares around $331. While the headlines are…
22 December 2025
····
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Dec. 22, 2025 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is stepping into a new tier of market visibility today as its Nasdaq-100 Index membership takes effect ahead of the opening bell—an index catalyst that can influence near-term trading and broaden long-term institutional ownership. Nasdaq ALNY was trading around $405.60 on Dec. 22 (time-stamped 16:37 UTC), up about 1.3% versus the…
22 December 2025
····
1 … 21 22 23 24 25 … 46

Stock Market Today

  • SRF Limited Sets Ex-Dividend Date for ₹5.00 Payout Amid Strong Earnings Growth
    January 22, 2026, 8:59 PM EST. SRF Limited (NSE:SRF) will trade ex-dividend from January 27, with a ₹5.00 per share dividend payable on February 17. The stock's trailing dividend yield stands at 0.4% based on a share price of ₹2,735.90. SRF's dividend payout is conservative, with only 15% of net income and free cash flow allocated for dividends, indicating sustainability. The company's earnings per share have grown by 13% annually over the past five years, supporting both dividend growth potential and reinvestment strategies. Investors seeking dividend income should consider timing purchases before the ex-dividend date to qualify for this payment.
Go toTop